(Q35818152)

10 August 2017

1 reference

title

Effect of drugs in secondary disease progression in patients with multiple sclerosis (English)

1 reference

10 August 2017

0 references

1

Ludwig Kappos

1 reference

10 August 2017

publication date

1 June 2004

1 reference

Multiple Sclerosis Journal

10 August 2017

published in

1 reference

10 August 2017

volume

10 Suppl 1

1 reference

10 August 2017

page(s)

S46-54; discussion S54-5

1 reference

The worldwide prevalence of multiple sclerosis

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Defining the clinical course of multiple sclerosis: Results of an international survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Medical hypothesis: why secondary progressive multiple sclerosis is a relentlessly progressive illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Immunopathology of secondary-progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

The Multiple Sclerosis Functional Composite: a new clinical outcome measure for multiple sclerosis trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Multiple sclerosis: the disease and its manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Serum inflammatory markers and clinical/MRI markers of disease progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

What is new in the treatment of multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Acute interferon beta-1b administration alters hypothalamic-pituitary-adrenal axis activity, plasma cytokines and leukocyte distribution in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Managing the adverse effects of interferon-beta therapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Multiple sclerosis: side effects of interferon beta therapy and their management

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Interferon-beta antibodies: implications for the treatment of MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

High-dose intravenous immunoglobulin treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Low dose oral methotrexate treatment of multiple sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Autologous hematopoietic stem cell transplantation suppresses Gd-enhanced MRI activity in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

Remyelinating strategies for the treatment of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F1352458504MS1030OA

10.1191/1352458504MS1030OA

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference